Molecular Partners AG (MOLN) Fair Value 2026

MOLN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.7 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (27/100)

Quick Summary — As of 2026-08-28, Molecular Partners AG (MOLN) trades at $4.50. QOC: 4.7/10. Value Trap Risk: 27/100 (LOW). 1/13 models active.

Key Facts

Ticker
MOLN
Price
$4.50
Quality Score
4.7/10
Value Trap Risk
27/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.7/10 signals weak fundamentals

What Fair Value Does Each Model Give MOLN?

1 Intrinsic Value Models vs. Current Price ($4.50)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $1.64 -63.5%

All Models Active

All 1 models are displayed above.

What Is Molecular Partners AG (MOLN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Molecular Partners AG's intrinsic value is estimated at $1.64. Trading at its current price of $4.50, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -63.5%.

What Do the Models Say About MOLN?

1 of 13 models are currently active for MOLN. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does MOLN Rank in Biotechnology?

Among 625 Biotechnology stocks, MOLN ranks #395 by Quality of Company score. CirclFi's QOC score of 4.7/10 evaluates 32 fundamental signals. A score of 4.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Molecular Partners AG's positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including platform technology validation — shape both the opportunity set and risk profile.

Is MOLN a Value Trap?

CirclFi's Value Trap algorithm assigns MOLN a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Molecular Partners AG. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Molecular Partners AG earns a quality score of 4.7/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every MOLN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across MOLN's 1 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Molecular Partners AG Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

LRMRLarimar Therapeutics, Inc.QOC 4.7MISTMilestone Pharmaceuticals Inc.QOC 4.7ENGNenGene Therapeutics Inc.QOC 4.7EWTXEdgewise Therapeutics, Inc.QOC 4.7TYRATyra Biosciences, Inc.QOC 4.7CBIOCrescent Biopharma, Inc.QOC 4.7ACUTAccuStem Sciences, Inc.QOC 3.8TVTXTravere Therapeutics, Inc.QOC 6.5SLXNSilexion Therapeutics CorpQOC 5.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: LRMR · MIST · ENGN · EWTX · TYRA · CBIO · ACUT · TVTX · SLXN · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to MOLN?

5 companies across all industries closest to MOLN’s Quality of Company score of 4.7/10.

HYORHyOrc CorporationQOC 4.7AEHLAntelope Enterprise Holdings LimitedQOC 4.7PAYPPayPay CorporationQOC 4.7CCNBCoastal Carolina Bancshares, Inc.QOC 4.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: HYOR · AEHL · PAYP · CCNB · NVDA

Where Does MOLN Sit in CirclFi's Biotechnology Rankings?

MOLN is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Molecular Partners AG’s Valuation?

What is Molecular Partners AG's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Molecular Partners AG (MOLN). The Quality of Company score is 4.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is MOLN overvalued or undervalued right now?

At $4.50, 0 of 1 active models suggest MOLN may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Molecular Partners AG's business model in Biotechnology.

What does a Quality of Company score of 4.7 mean for MOLN?

Molecular Partners AG's QOC of 4.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on MOLN?

CirclFi analyzes MOLN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is MOLN a value trap in 2026?

Molecular Partners AG's Value Trap score is 27/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Molecular Partners AG (MOLN) a Quality of Company score of 4.7/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/MOLN/ · Methodology
Primary sources for this MOLN valuation
  • Financial statements: Molecular Partners AG 10-K and 10-Q filings on SEC EDGAR (CIK 0001745114) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for MOLN as of ; valuations recomputed .